C4 Therapeutics Abandons BRAF Inhibitor to Fully Focus on Multiple Myeloma Treatment

C4 Therapeutics Abandons BRAF Inhibitor to Fully Focus on Multiple Myeloma Treatment

C4 Therapeutics Abandons BRAF Inhibitor to Fully Focus on Multiple Myeloma Treatment